BACKGROUND: The benefit of postoperative radiotherapy (PORT) for early squamous cell carcinoma of the tongue (SCCOT) with pathologic N1 disease remains unclear. METHODS: The medical records of all patients with pathologic T1-2/N0-1 SCCOT who underwent wide excision of the primary tumor and neck dissection between 1980 and 2002 were reviewed. RESULTS: There were 59 patients analyzed, including 28 patients with and 31 patients without PORT. The 5-year disease-free survival rates were 81.2% and 53% for the patients with and without PORT, respectively (p = .03). The overall 5-year survival rates were 77% and 70.5% for the patients with and without PORT, respectively (p = .36). Multivariate analyses showed that PORT had the only protective effect (p = .01) and extracapsular spread (ECS) was the only significantly adverse factor for locoregional recurrence (p = .03). CONCLUSIONS: Approximately one-third of the patients who received only surgery had locoregional recurrence. PORT significantly improved the disease-free survival.
BACKGROUND: The benefit of postoperative radiotherapy (PORT) for early squamous cell carcinoma of the tongue (SCCOT) with pathologic N1 disease remains unclear. METHODS: The medical records of all patients with pathologic T1-2/N0-1 SCCOT who underwent wide excision of the primary tumor and neck dissection between 1980 and 2002 were reviewed. RESULTS: There were 59 patients analyzed, including 28 patients with and 31 patients without PORT. The 5-year disease-free survival rates were 81.2% and 53% for the patients with and without PORT, respectively (p = .03). The overall 5-year survival rates were 77% and 70.5% for the patients with and without PORT, respectively (p = .36). Multivariate analyses showed that PORT had the only protective effect (p = .01) and extracapsular spread (ECS) was the only significantly adverse factor for locoregional recurrence (p = .03). CONCLUSIONS: Approximately one-third of the patients who received only surgery had locoregional recurrence. PORT significantly improved the disease-free survival.
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Maximilian Moergel; Philipp Meurer; Katharina Ingel; Thomas G Wendt; Bilal Al-Nawas Journal: Strahlenther Onkol Date: 2011-05-16 Impact factor: 3.621
Authors: Nootan Kumar Shukla; S V Suryanarayana Deo; Pankaj Kumar Garg; N M L Manjunath; Suman Bhaskar; V Sreenivas Journal: Indian J Surg Oncol Date: 2017-05-11